Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Uterine fibroids are benign tumors originating from the smooth muscle of the uterus. Treatment options include a range of pharmacological approaches and/or surgical procedures. NSAIDs such as ibuprofen and naproxen help alleviate pain but do not reduce the size of the fibroids. Progestins (e.g., norethindrone, levonorgestrel) in hormonal contraceptives and intrauterine devices reduce the heavy bleeding and cramping associated with fibroids. Combination hormonal contraceptives (e.g., Sumitovant / Pfizer’s Myfembree, approved in 2021) and antifibrinolytics such as tranexamic acid can regulate menstrual cycles. Vitamins and supplements support health but do not affect fibroids. Gonadotropin-releasing hormone (GnRH) agonists (e.g., leuprolide) modify hormone levels and can shrink fibroids presurgery but have side effects that limit their long-term use. This analysis of U.S. patient-level claims data explores the use of various drug classes in both newly diagnosed and recently treated patients, providing insight into the current treatment paradigm for uterine fibroids.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed uterine fibroid patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed uterine fibroid patients?
- How have NSAIDs, progestins, combination hormonal contraceptives, vitamins, antifibrinolytics, and other therapies been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of uterine fibroid patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of uterine fibroid patients are treated with a single drug or fixed-dose combination versus a combination of separate products? What are the separate products most commonly used in combination?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key drugs: NSAIDs, progestins, combination hormonal contraceptives, vitamins, antifibrinolytics
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses.
